{
  "id": "resp_04f3c5fa11fb238200693c8aaadba081908e50046181753d0f",
  "object": "response",
  "created_at": 1765575338,
  "status": "completed",
  "background": false,
  "billing": {
    "payer": "developer"
  },
  "error": null,
  "incomplete_details": null,
  "instructions": null,
  "max_output_tokens": null,
  "max_tool_calls": null,
  "model": "gpt-5.2-2025-12-11",
  "output": [
    {
      "id": "rs_04f3c5fa11fb238200693c8aab3f948190817a0e06ee894c16",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_04f3c5fa11fb238200693c8aadd0e881909d18946da75bee60",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "CDK12/13 inhibitor triple negative breast cancer press release trial"
      }
    },
    {
      "id": "rs_04f3c5fa11fb238200693c8ab0daf48190b31c3220da073eb2",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_04f3c5fa11fb238200693c8ab32f10819088c9fa5ba68bab64",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "NCT06600789 CT7439 CDK12/13 trial breast"
      }
    },
    {
      "id": "rs_04f3c5fa11fb238200693c8ab556c88190a15caf46231df6b5",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_04f3c5fa11fb238200693c8ab5d7b08190bd3923f3d6abfede",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "site:clinicaltrials.gov NCT06600789"
      }
    },
    {
      "id": "rs_04f3c5fa11fb238200693c8ab7ae00819095a33cd689de7587",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_04f3c5fa11fb238200693c8abf99288190a850116dad656755",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html"
      }
    },
    {
      "id": "rs_04f3c5fa11fb238200693c8ac29b4c8190953d4c9846a58b0e",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_04f3c5fa11fb238200693c8ac3508881908f1dcc30d21df0ad",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "find_in_page",
        "pattern": "ZLC491",
        "url": "https://pubmed.ncbi.nlm.nih.gov/39388374/"
      }
    },
    {
      "id": "rs_04f3c5fa11fb238200693c8ac4cc748190880a31a28e96c70a",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_04f3c5fa11fb238200693c8ac72b948190b79ac5b5d1934e82",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "find_in_page",
        "pattern": "Here, we report",
        "url": "https://pubmed.ncbi.nlm.nih.gov/39388374/"
      }
    },
    {
      "id": "rs_04f3c5fa11fb238200693c8ac9c1908190ae5cc53513e02107",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_04f3c5fa11fb238200693c8acbab5c8190a3d56ce49ce8b18a",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page"
      }
    },
    {
      "id": "rs_04f3c5fa11fb238200693c8ace6a0881908d8d957eecdf5778",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_04f3c5fa11fb238200693c8ad060388190be65a719bafe8c28",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "https://clinicaltrials.gov/study/NCT06600789"
      }
    },
    {
      "id": "rs_04f3c5fa11fb238200693c8ad22fd88190b654a9e5fc6e8f09",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_04f3c5fa11fb238200693c8ad3bd508190b226d30c8cd87137",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://clinicaltrials.gov/study/NCT06600789"
      }
    },
    {
      "id": "rs_04f3c5fa11fb238200693c8ad49b408190a18765d8cee58b60",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_04f3c5fa11fb238200693c8ad783b88190972e33f0876ea472",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://pubmed.ncbi.nlm.nih.gov/38104154/"
      }
    },
    {
      "id": "rs_04f3c5fa11fb238200693c8ad8bc0481909d9cdd3c8a8eec01",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_04f3c5fa11fb238200693c8ad90e6c81908561275251ac51d8",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "find_in_page",
        "pattern": "7f",
        "url": "https://pubmed.ncbi.nlm.nih.gov/35938508/"
      }
    },
    {
      "id": "rs_04f3c5fa11fb238200693c8adb60a88190aeaffb799824c45d",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_04f3c5fa11fb238200693c8ae483508190bf1b955704d13e33",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://cdek.pharmacy.purdue.edu/trial/NCT06600789/"
      }
    },
    {
      "id": "rs_04f3c5fa11fb238200693c8ae61a408190a6cc8986d1a3e074",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_04f3c5fa11fb238200693c8ae8e4d081909f3360637101f35e",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12435847/"
      }
    },
    {
      "id": "rs_04f3c5fa11fb238200693c8ae9d7648190b8ad9514068dd347",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_04f3c5fa11fb238200693c8aea71648190a5cd8673d5172f02",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "find_in_page",
        "pattern": "CT7439"
      }
    },
    {
      "id": "rs_04f3c5fa11fb238200693c8aec7db48190985854e546af5691",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_04f3c5fa11fb238200693c8aee82508190912aa8ff8f79d99e",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://www.cancernetwork.com/view/fda-clears-ind-application-for-first-in-class-cdk12-13-inhibitor"
      }
    },
    {
      "id": "rs_04f3c5fa11fb238200693c8aef6f448190b3830c38f4d83fca",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "msg_04f3c5fa11fb238200693c8afb94108190afa5c2fd0f587fc9",
      "type": "message",
      "status": "completed",
      "content": [
        {
          "type": "output_text",
          "annotations": [
            {
              "type": "url_citation",
              "end_index": 514,
              "start_index": 314,
              "title": "Carrick Therapeutics Announces First Patient Dosed in Phase",
              "url": "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html"
            },
            {
              "type": "url_citation",
              "end_index": 882,
              "start_index": 682,
              "title": "Carrick Therapeutics Announces First Patient Dosed in Phase",
              "url": "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html"
            },
            {
              "type": "url_citation",
              "end_index": 1185,
              "start_index": 985,
              "title": "Carrick Therapeutics Announces First Patient Dosed in Phase",
              "url": "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html"
            },
            {
              "type": "url_citation",
              "end_index": 1508,
              "start_index": 1308,
              "title": "Carrick Therapeutics Announces First Patient Dosed in Phase",
              "url": "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html"
            },
            {
              "type": "url_citation",
              "end_index": 1952,
              "start_index": 1785,
              "title": "Carrick Therapeutics Announces U.S. FDA Clearance of IND for CT7439, a First-In-Class Inhibitor of CDK12/13 :: Carrick Therapeutics, Inc.",
              "url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind"
            },
            {
              "type": "url_citation",
              "end_index": 2323,
              "start_index": 2156,
              "title": "Carrick Therapeutics Announces U.S. FDA Clearance of IND for CT7439, a First-In-Class Inhibitor of CDK12/13 :: Carrick Therapeutics, Inc.",
              "url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind"
            },
            {
              "type": "url_citation",
              "end_index": 2686,
              "start_index": 2519,
              "title": "Carrick Therapeutics Announces U.S. FDA Clearance of IND for CT7439, a First-In-Class Inhibitor of CDK12/13 :: Carrick Therapeutics, Inc.",
              "url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind"
            },
            {
              "type": "url_citation",
              "end_index": 2936,
              "start_index": 2769,
              "title": "Carrick Therapeutics Announces U.S. FDA Clearance of IND for CT7439, a First-In-Class Inhibitor of CDK12/13 :: Carrick Therapeutics, Inc.",
              "url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind"
            },
            {
              "type": "url_citation",
              "end_index": 3160,
              "start_index": 3079,
              "title": "\n\n    \n        Trial | NCT06600789\n    \n\n",
              "url": "https://cdek.pharmacy.purdue.edu/trial/NCT06600789/"
            },
            {
              "type": "url_citation",
              "end_index": 3336,
              "start_index": 3255,
              "title": "\n\n    \n        Trial | NCT06600789\n    \n\n",
              "url": "https://cdek.pharmacy.purdue.edu/trial/NCT06600789/"
            },
            {
              "type": "url_citation",
              "end_index": 3459,
              "start_index": 3378,
              "title": "\n\n    \n        Trial | NCT06600789\n    \n\n",
              "url": "https://cdek.pharmacy.purdue.edu/trial/NCT06600789/"
            },
            {
              "type": "url_citation",
              "end_index": 3563,
              "start_index": 3482,
              "title": "\n\n    \n        Trial | NCT06600789\n    \n\n",
              "url": "https://cdek.pharmacy.purdue.edu/trial/NCT06600789/"
            },
            {
              "type": "url_citation",
              "end_index": 3991,
              "start_index": 3828,
              "title": "A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies | Clinical Research Trial Listing",
              "url": "https://www.centerwatch.com/clinical-trials/listings/NCT06600789/a-modular-phase-1-2-study-with-ct7439-in-participants-with-solid-malignancies"
            },
            {
              "type": "url_citation",
              "end_index": 4275,
              "start_index": 4112,
              "title": "A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies | Clinical Research Trial Listing",
              "url": "https://www.centerwatch.com/clinical-trials/listings/NCT06600789/a-modular-phase-1-2-study-with-ct7439-in-participants-with-solid-malignancies"
            },
            {
              "type": "url_citation",
              "end_index": 4476,
              "start_index": 4313,
              "title": "A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies | Clinical Research Trial Listing",
              "url": "https://www.centerwatch.com/clinical-trials/listings/NCT06600789/a-modular-phase-1-2-study-with-ct7439-in-participants-with-solid-malignancies"
            },
            {
              "type": "url_citation",
              "end_index": 4751,
              "start_index": 4588,
              "title": "A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies | Clinical Research Trial Listing",
              "url": "https://www.centerwatch.com/clinical-trials/listings/NCT06600789/a-modular-phase-1-2-study-with-ct7439-in-participants-with-solid-malignancies"
            },
            {
              "type": "url_citation",
              "end_index": 5084,
              "start_index": 4962,
              "title": "FDA Clears IND Application for First-in-Class CDK12/13 Inhibitor  | CancerNetwork",
              "url": "https://www.cancernetwork.com/view/fda-clears-ind-application-for-first-in-class-cdk12-13-inhibitor"
            },
            {
              "type": "url_citation",
              "end_index": 5307,
              "start_index": 5185,
              "title": "FDA Clears IND Application for First-in-Class CDK12/13 Inhibitor  | CancerNetwork",
              "url": "https://www.cancernetwork.com/view/fda-clears-ind-application-for-first-in-class-cdk12-13-inhibitor"
            },
            {
              "type": "url_citation",
              "end_index": 5482,
              "start_index": 5360,
              "title": "FDA Clears IND Application for First-in-Class CDK12/13 Inhibitor  | CancerNetwork",
              "url": "https://www.cancernetwork.com/view/fda-clears-ind-application-for-first-in-class-cdk12-13-inhibitor"
            },
            {
              "type": "url_citation",
              "end_index": 5671,
              "start_index": 5549,
              "title": "FDA Clears IND Application for First-in-Class CDK12/13 Inhibitor  | CancerNetwork",
              "url": "https://www.cancernetwork.com/view/fda-clears-ind-application-for-first-in-class-cdk12-13-inhibitor"
            },
            {
              "type": "url_citation",
              "end_index": 5892,
              "start_index": 5822,
              "title": "Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/31668947/"
            },
            {
              "type": "url_citation",
              "end_index": 6159,
              "start_index": 6089,
              "title": "Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/31668947/"
            },
            {
              "type": "url_citation",
              "end_index": 6355,
              "start_index": 6285,
              "title": "Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/31668947/"
            },
            {
              "type": "url_citation",
              "end_index": 6639,
              "start_index": 6569,
              "title": "Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/34864331/"
            },
            {
              "type": "url_citation",
              "end_index": 6815,
              "start_index": 6745,
              "title": "Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/34864331/"
            },
            {
              "type": "url_citation",
              "end_index": 7019,
              "start_index": 6949,
              "title": "Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/34864331/"
            },
            {
              "type": "url_citation",
              "end_index": 7184,
              "start_index": 7114,
              "title": "Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/34864331/"
            },
            {
              "type": "url_citation",
              "end_index": 7428,
              "start_index": 7358,
              "title": "Discovery of ZLC491 as a Potent, Selective, and Orally Bioavailable CDK12/13 PROTAC Degrader - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/39388374/"
            },
            {
              "type": "url_citation",
              "end_index": 7610,
              "start_index": 7540,
              "title": "Discovery of ZLC491 as a Potent, Selective, and Orally Bioavailable CDK12/13 PROTAC Degrader - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/39388374/"
            },
            {
              "type": "url_citation",
              "end_index": 7785,
              "start_index": 7715,
              "title": "Discovery of ZLC491 as a Potent, Selective, and Orally Bioavailable CDK12/13 PROTAC Degrader - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/39388374/"
            },
            {
              "type": "url_citation",
              "end_index": 7923,
              "start_index": 7853,
              "title": "Discovery of ZLC491 as a Potent, Selective, and Orally Bioavailable CDK12/13 PROTAC Degrader - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/39388374/"
            },
            {
              "type": "url_citation",
              "end_index": 8157,
              "start_index": 8087,
              "title": "Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13 - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/35938508/"
            },
            {
              "type": "url_citation",
              "end_index": 8339,
              "start_index": 8269,
              "title": "Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13 - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/35938508/"
            },
            {
              "type": "url_citation",
              "end_index": 8515,
              "start_index": 8445,
              "title": "Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13 - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/35938508/"
            },
            {
              "type": "url_citation",
              "end_index": 8660,
              "start_index": 8590,
              "title": "Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13 - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/35938508/"
            },
            {
              "type": "url_citation",
              "end_index": 8916,
              "start_index": 8846,
              "title": "The CDK12 inhibitor SR-4835 functions as a molecular glue that promotes cyclin K degradation in melanoma - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/38104154/"
            },
            {
              "type": "url_citation",
              "end_index": 9091,
              "start_index": 9021,
              "title": "The CDK12 inhibitor SR-4835 functions as a molecular glue that promotes cyclin K degradation in melanoma - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/38104154/"
            },
            {
              "type": "url_citation",
              "end_index": 9235,
              "start_index": 9165,
              "title": "The CDK12 inhibitor SR-4835 functions as a molecular glue that promotes cyclin K degradation in melanoma - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/38104154/"
            },
            {
              "type": "url_citation",
              "end_index": 9345,
              "start_index": 9275,
              "title": "The CDK12 inhibitor SR-4835 functions as a molecular glue that promotes cyclin K degradation in melanoma - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/38104154/"
            }
          ],
          "logprobs": [],
          "text": "- **Title:** Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor)  \n  **URL:** `https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html` ([globenewswire.com](https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html))  \n  **Direct quotes (identifiers/targets/modalities/indications):**\n  - “CT7439, a novel cyclin dependent kinase 12/13 (CDK12/13) inhibitor / Cyclin-K glue-degrader.” ([globenewswire.com](https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html))\n  - “Clinical trial details can also be found on www.clinicaltrials.gov under study ID: NCT06600789.” ([globenewswire.com](https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html))\n  - “The clinical trial is enrolling patients with advanced solid tumors, including ovarian, breast and Ewing's Sarcoma.” ([globenewswire.com](https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html))\n\n- **Title:** Carrick Therapeutics Announces U.S. FDA Clearance of IND for CT7439, a First-In-Class Inhibitor of CDK12/13  \n  **URL:** `https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind` ([carricktherapeutics.com](https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind))  \n  **Direct quotes (identifiers/targets/modalities/indications):**\n  - “the Company’s Investigational New Drug (IND) application for CT7439, a novel cyclin dependent kinase 12/13 (CDK12/13) inhibitor.” ([carricktherapeutics.com](https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind))\n  - “The Company plans to initiate the Phase 1 clinical trial in the first half of 2024 and intends to enroll patients with advanced solid tumors, including breast, ovarian and Ewing's Sarcoma.” ([carricktherapeutics.com](https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind))\n  - “CT7439 is an inhibitor of CDK12/13 as well as a 'glue degrader' of Cyclin-K” ([carricktherapeutics.com](https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind))\n\n- **Title:** Trial | NCT06600789 (Clinical Drug Experience Knowledgebase)  \n  **URL:** `https://cdek.pharmacy.purdue.edu/trial/NCT06600789/` ([cdek.pharmacy.purdue.edu](https://cdek.pharmacy.purdue.edu/trial/NCT06600789/))  \n  **Direct quotes (identifiers/targets/modalities/indications):**\n  - “Trial | NCT06600789” ([cdek.pharmacy.purdue.edu](https://cdek.pharmacy.purdue.edu/trial/NCT06600789/))\n  - “CT7439 Capsules (0.5 mg, 1mg, 3mg)” ([cdek.pharmacy.purdue.edu](https://cdek.pharmacy.purdue.edu/trial/NCT06600789/))\n  - “Phase 1/Phase 2” ([cdek.pharmacy.purdue.edu](https://cdek.pharmacy.purdue.edu/trial/NCT06600789/))\n\n- **Title:** A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies (CenterWatch)  \n  **URL:** `https://www.centerwatch.com/clinical-trials/listings/NCT06600789/a-modular-phase-1-2-study-with-ct7439-in-participants-with-solid-malignancies` ([centerwatch.com](https://www.centerwatch.com/clinical-trials/listings/NCT06600789/a-modular-phase-1-2-study-with-ct7439-in-participants-with-solid-malignancies))  \n  **Direct quotes (identifiers/targets/modalities/indications):**\n  - “Treatment  CT7439 Capsules (0.5 mg, 1mg, 3mg)” ([centerwatch.com](https://www.centerwatch.com/clinical-trials/listings/NCT06600789/a-modular-phase-1-2-study-with-ct7439-in-participants-with-solid-malignancies))\n  - “Clinical Study ID  NCT06600789” ([centerwatch.com](https://www.centerwatch.com/clinical-trials/listings/NCT06600789/a-modular-phase-1-2-study-with-ct7439-in-participants-with-solid-malignancies))\n  - “Prior therapy with a specific CDK12/13 inhibitor, within any timeframe prior to thefirst dose of CT7439.” ([centerwatch.com](https://www.centerwatch.com/clinical-trials/listings/NCT06600789/a-modular-phase-1-2-study-with-ct7439-in-participants-with-solid-malignancies))\n\n- **Title:** FDA Clears IND Application for First-in-Class CDK12/13 Inhibitor (CancerNetwork)  \n  **URL:** `https://www.cancernetwork.com/view/fda-clears-ind-application-for-first-in-class-cdk12-13-inhibitor` ([cancernetwork.com](https://www.cancernetwork.com/view/fda-clears-ind-application-for-first-in-class-cdk12-13-inhibitor))  \n  **Direct quotes (identifiers/targets/modalities/indications):**\n  - “CDK12/13 inhibitor CT7439” ([cancernetwork.com](https://www.cancernetwork.com/view/fda-clears-ind-application-for-first-in-class-cdk12-13-inhibitor))\n  - “The compound is a “glue degrader” of Cyclin-K” ([cancernetwork.com](https://www.cancernetwork.com/view/fda-clears-ind-application-for-first-in-class-cdk12-13-inhibitor))\n  - “including breast cancer, ovarian cancer, and Ewing sarcoma.” ([cancernetwork.com](https://www.cancernetwork.com/view/fda-clears-ind-application-for-first-in-class-cdk12-13-inhibitor))\n\n- **Title:** Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer (PubMed)  \n  **URL:** `https://pubmed.ncbi.nlm.nih.gov/31668947/` ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31668947/))  \n  **Direct quotes (identifiers/targets/modalities/indications):**\n  - “SR-4835, a highly selective dual inhibitor of CDK12 and CDK13, which disables triple-negative breast cancer (TNBC) cells.” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31668947/))\n  - “Keywords:  BRCAness; CDK12; CDK13; PARP inhibitor; cisplatin; intronic polyadenylation; triple-negative breast cancer.” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31668947/))\n\n- **Title:** Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor (PubMed)  \n  **URL:** `https://pubmed.ncbi.nlm.nih.gov/34864331/` ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/34864331/))  \n  **Direct quotes (identifiers/targets/modalities/indications):**\n  - “a potent PROTAC degrader PP-C8” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/34864331/))\n  - “PP-C8 demonstrates profound synergistic antiproliferative effects with PARP inhibitor in triple-negative breast cancer (TNBC).” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/34864331/))\n  - “Keywords:  CDK12; Cyclin K; PROTAC; Synthetic lethality; Triple-negative breast cancer.” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/34864331/))\n\n- **Title:** Discovery of ZLC491 as a Potent, Selective, and Orally Bioavailable CDK12/13 PROTAC Degrader (PubMed)  \n  **URL:** `https://pubmed.ncbi.nlm.nih.gov/39388374/` ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39388374/))  \n  **Direct quotes (identifiers/targets/modalities/indications):**\n  - “triple-negative breast cancer (TNBC)” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39388374/))\n  - “the discovery of ZLC491 as a potent, selective, and orally bioavailable CDK12/13 PROTAC degrader.” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39388374/))\n  - “degraded CDK12 and CDK13 with DC_{50} values of 32 and 28 nM” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39388374/))\n\n- **Title:** Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13 (PubMed)  \n  **URL:** `https://pubmed.ncbi.nlm.nih.gov/35938508/` ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35938508/))  \n  **Direct quotes (identifiers/targets/modalities/indications):**\n  - “triple-negative breast cancer (TNBC)” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35938508/))\n  - “The optimal compound 7f effectively degraded CDK12 and CDK13 with DC_{50} values of 2.2 and 2.1 nM” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35938508/))\n  - “by employing the proteolysis-targeting chimera (PROTAC) technology.” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35938508/))\n\n- **Title:** The CDK12 inhibitor SR-4835 functions as a molecular glue that promotes cyclin K degradation in melanoma (PubMed)  \n  **URL:** `https://pubmed.ncbi.nlm.nih.gov/38104154/` ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38104154/))  \n  **Direct quotes (identifiers/targets/modalities/indications):**\n  - “including THZ531 and SR-4835.” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38104154/))\n  - “SR-4835 uniquely promotes cyclin K degradation via the proteasome.” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38104154/))\n  - “SR-4835 acts as a molecular glue” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38104154/))"
        }
      ],
      "role": "assistant"
    }
  ],
  "parallel_tool_calls": true,
  "previous_response_id": null,
  "prompt_cache_key": null,
  "prompt_cache_retention": null,
  "reasoning": {
    "effort": "medium",
    "summary": null
  },
  "safety_identifier": null,
  "service_tier": "default",
  "store": true,
  "temperature": 1.0,
  "text": {
    "format": {
      "type": "text"
    },
    "verbosity": "medium"
  },
  "tool_choice": "auto",
  "tools": [
    {
      "type": "web_search",
      "filters": null,
      "search_context_size": "medium",
      "user_location": {
        "type": "approximate",
        "city": null,
        "country": "US",
        "region": null,
        "timezone": null
      }
    }
  ],
  "top_logprobs": 0,
  "top_p": 0.98,
  "truncation": "disabled",
  "usage": {
    "input_tokens": 55676,
    "input_tokens_details": {
      "cached_tokens": 4352
    },
    "output_tokens": 5912,
    "output_tokens_details": {
      "reasoning_tokens": 3852
    },
    "total_tokens": 61588
  },
  "user": null,
  "metadata": {}
}